Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01600326 · ClinicalTrials.gov registry record · Phase 2
A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection
A Phase 2 study of Tendinosis and Tendinitis, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01600326: Completed Phase 2 study of Tendinosis and Tendinitis, sponsored by University of Michigan.
NCT01600326 is a Phase 2 study of Tendinosis and Tendinitis that has completed, run by University of Michigan. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01600326, a Phase 2 study of Tendinosis and Tendinitis, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of various treatment soft tendinosis also known as tendinitis.
Primary Outcome
Patient symptoms are measured on a 50 point scale where 0 is no pain or interference with activities and 50 is highest pain and interference. A verbal evaluation and assessment of subject's pain and symptoms will be completed prior to treatment. After receiving medication a second evaluation will be taken to determine how well the medication has relieved and controlled the subject's pain and inflammation associated with tendinitis. Subjects will be specifically asked to rate the level of pain
Conditions Studied
Interventions
- PROCEDURE Tenotomy (no injection)
- DRUG Ultrasound guided platelet rich plasma injection
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT01600326 record still lists
NCT01600326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Tendinosis appearing as the primary indexed condition, and to 2 interventions - of which Tenotomy (no injection) is the first listed.
NCT01600326 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01600326 about?
NCT01600326 is a clinical study titled "A Prospective Comparison of Ultrasound-Guided Percutaneous Platelet-Rich Plasma Injection". The purpose of this study is to determine the effectiveness of various treatment soft tendinosis also known as tendinitis.
What is the current status of trial NCT01600326?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2010-07. Estimated completion is 2015-07.
What conditions does trial NCT01600326 study?
This clinical trial studies the following conditions: Tendinosis, Tendinitis.
What interventions are being tested in trial NCT01600326?
The interventions under investigation include: Tenotomy (no injection) (PROCEDURE), Ultrasound guided platelet rich plasma injection (DRUG).
Who is sponsoring clinical trial NCT01600326?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01600326 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tendinosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01600326's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia